Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANYNASDAQ:MCVTNASDAQ:NCPLNASDAQ:NRBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANYSphere 3D$0.47-1.1%$0.72$0.45▼$1.90$11.96M3.11579,785 shs178,999 shsMCVTMill City Ventures III$1.81-0.5%$2.26$1.65▼$3.88$11.56M0.56102,625 shs15,665 shsNCPLNetcapital$1.74-3.3%$2.03$1.41▼$22.85$3.81M-0.48228,517 shs30,188 shsNRBONeuroBo Pharmaceuticals$1.58+1.9%$1.69$2.08▼$5.30$13.61M-0.2646,180 shs39,387 shsThe 10 Best Stocks to Own: Spring 2025Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANYSphere 3D-1.06%-3.85%-28.69%-52.97%-65.58%MCVTMill City Ventures III+1.11%-1.62%-10.78%-4.71%-30.27%NCPLNetcapital+7.14%-4.26%-21.40%-5.76%-79.96%NRBONeuroBo Pharmaceuticals0.00%+4.73%-5.49%-4.91%-65.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANYSphere 3D1.8131 of 5 stars3.53.00.00.01.30.00.6MCVTMill City Ventures III0.7157 of 5 stars0.03.00.00.00.03.30.6NCPLNetcapital0.2413 of 5 stars0.02.00.00.01.70.00.6NRBONeuroBo Pharmaceuticals1.1273 of 5 stars3.50.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANYSphere 3D 3.00Buy$3.00538.30% UpsideMCVTMill City Ventures III 0.00N/AN/AN/ANCPLNetcapital 0.00N/AN/AN/ANRBONeuroBo Pharmaceuticals 3.00Buy$10.00532.91% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANYSphere 3D$21.66M0.55N/AN/A$1.85 per share0.25MCVTMill City Ventures III$3.57M3.24N/AN/A$2.91 per share0.62NCPLNetcapital$812.61K4.69N/AN/A$115.96 per share0.02NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANYSphere 3D-$23.41M-$0.80N/AN/AN/A-50.87%-49.54%-34.72%5/12/2025 (Estimated)MCVTMill City Ventures III-$1.17M$0.06N/A∞N/A-12.15%1.44%1.42%3/31/2025 (Estimated)NCPLNetcapital-$4.99M-$20.20N/A1.24N/A-562.71%-25.03%-22.67%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%3/27/2025 (Estimated)Latest NCPL, NRBO, ANY, and MCVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025N/ANRBONeuroBo Pharmaceuticals-$0.89N/AN/AN/AN/AN/A3/17/2025Q3 2025NCPLNetcapital-$0.70-$1.57-$0.87-$1.57$1.13 million$0.15 million3/10/2025Q4 2024MCVTMill City Ventures IIIN/A$0.01N/A-$0.01N/A$0.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANYSphere 3DN/AN/AN/AN/AN/AMCVTMill City Ventures IIIN/AN/AN/AN/AN/ANCPLNetcapitalN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANYSphere 3DN/A4.094.09MCVTMill City Ventures IIIN/A6.836.83NCPLNetcapitalN/A0.350.35NRBONeuroBo PharmaceuticalsN/A2.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANYSphere 3D17.28%MCVTMill City Ventures III11.61%NCPLNetcapital30.69%NRBONeuroBo Pharmaceuticals1.37%Insider OwnershipCompanyInsider OwnershipANYSphere 3D5.59%MCVTMill City Ventures III26.52%NCPLNetcapital6.77%NRBONeuroBo Pharmaceuticals1.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANYSphere 3D2025.45 million24.03 millionOptionableMCVTMill City Ventures III26.39 million4.69 millionNot OptionableNCPLNetcapitalN/A2.19 million1.72 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableNCPL, NRBO, ANY, and MCVT HeadlinesRecent News About These CompaniesNeuroBo Pharmaceuticals (NRBO) Projected to Post Quarterly Earnings on ThursdayMarch 25 at 2:03 AM | americanbankingnews.comMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals rebrands to become MetaViaNovember 19, 2024 | fiercepharma.comNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNovember 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap EventNovember 12, 2024 | bignewsnetwork.comNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNovember 4, 2024 | prnewswire.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…October 2, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberOctober 1, 2024 | prnewswire.comNeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity TreatmentSeptember 30, 2024 | markets.businessinsider.comWe're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn RateSeptember 30, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesitySeptember 30, 2024 | prnewswire.comNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comNRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…August 21, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBigBear.ai: Is It Opportunity Knocking or a Trap Door?By Jeffrey Neal Johnson | February 25, 2025View BigBear.ai: Is It Opportunity Knocking or a Trap Door?These 3 Iconic Brands Just Announced Bigger Dividend PayoutsBy Leo Miller | March 7, 2025View These 3 Iconic Brands Just Announced Bigger Dividend PayoutsIntuitive Machines: March 6 Is a Pivotal Day for Lunar EconomyBy Leo Miller | March 4, 2025View Intuitive Machines: March 6 Is a Pivotal Day for Lunar Economy3 Stocks to Buy While Others Stay on the SidelinesBy Chris Markoch | March 8, 2025View 3 Stocks to Buy While Others Stay on the Sidelines4 EV Stocks Facing Uncertainty—Which Ones Will Survive?By Thomas Hughes | March 7, 2025View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?NCPL, NRBO, ANY, and MCVT Company DescriptionsSphere 3D NASDAQ:ANY$0.47 -0.01 (-1.05%) Closing price 04:00 PM EasternExtended Trading$0.49 +0.02 (+3.62%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sphere 3D Corp. engages in the bitcoin mining business. It is involved with digital asset mining pool operators to provide computing power to the mining pools. The company is based in Stamford, Connecticut.Mill City Ventures III NASDAQ:MCVT$1.81 -0.01 (-0.55%) Closing price 04:00 PM EasternExtended Trading$1.83 +0.02 (+1.10%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mill City Ventures III, Ltd. is a principal investment firm specializing investments in debt and equity securities of public and private companies to fund their operations whether its start-up, acquisition, or growth. It primarily focuses on investing in, lending to, and making managerial assistance available to privately held and publicly traded companies. The firm also advises its portfolio companies with regard to finance and operations. It was formerly known as Poker Magic, Inc. Mill City Ventures III, Ltd. was founded in January, 2006 and is based in Wayzata, Minnesota.Netcapital NASDAQ:NCPL$1.74 -0.06 (-3.33%) Closing price 03:59 PM EasternExtended Trading$1.76 +0.02 (+1.15%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Netcapital Inc. operates as a fintech company. It offers Netcapital.com, an SEC-registered funding portal that enables private companies to raise capital online, as well as allows investors to invest from anywhere in the world. The company also provides various services, including automated onboarding process and filing of required regulatory documents; compliance review; custom-built offering page on its portal website; third party transfer agent and custodial services; and rolling closes which provides access to liquidity before final close date of offerings, as well as assistance with annual fillings and direct access to team for ongoing support. In addition, it offers advisor services, which includes incubation of technology start-ups; investors introduction; online marketing; website design and software development; message crafting including pitch decks, offering pages, and ad creation; strategic advice; and technology consulting services. Further, the company provides valuation services, such as business valuation, fairness and solvency opinions, ESOP feasibility and valuation, non-cash charitable contribution, economic analysis of damages, intellectual property appraisals, and compensation studies. Netcapital Inc. is based in Boston, Massachusetts.NeuroBo Pharmaceuticals NASDAQ:NRBO$1.58 +0.03 (+1.94%) As of 03/24/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
